

Editorial

# Glucose Metabolism Disorders: Challenges and Opportunities for Diagnosis and Treatment

Jelena Vekic<sup>1</sup>, José Silva-Nunes<sup>2</sup>  and Manfredi Rizzo<sup>3,\*</sup> 

- <sup>1</sup> Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia; jelena.vekic@pharmacy.bg.ac.rs
- <sup>2</sup> Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de Lisboa Central, 1069-166 Lisbon, Portugal; silvanunes2004@yahoo.com
- <sup>3</sup> Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90100 Palermo, Italy
- \* Correspondence: manfredi.rizzo@unipa.it

Alterations of glucose metabolism are recognized as one of the most important risk factors for the development and complications of cardiometabolic diseases. The relationship between glucose metabolism disorders and cardiometabolic diseases is complex and mediated by multiple dysregulated pathways. Insulin resistance, the main driving force of disturbed glucose homeostasis, is strongly associated with obesity and metabolic syndrome [1]. In addition to metabolic disorders, which include impaired glucose tolerance, abdominal obesity, decreased high-density lipoprotein cholesterol (HDL-C) level and elevated triglycerides (TG), metabolic syndrome is characterized by a procoagulant, proinflammatory and prooxidant state [2], which further increases the likelihood of developing ischemic cardiovascular (CVD) and cerebrovascular diseases. However, biomarkers of these processes are seldom evaluated in clinical practice and therefore require further validation.

In general, an abnormal peripheral tissue insulin sensitivity and pancreatic  $\beta$ -cell dysfunction are presented even before glucose level exceeds the optimal thresholds, which is increasingly acknowledged as prediabetes [3]. Currently, there is a growing support for the approach that individuals with prediabetes should be closely monitored in order to recognize early subtle changes which might assist to delay or prevent development of diabetes. In addition to individuals in prediabetes state, there are also certain vulnerable groups with impaired glucose metabolism who require further considerations. Women with gestational diabetes mellitus are prone to develop serious pregnancy complications, including preeclampsia, preterm birth, macrosomia and neonatal hypoglycemia [4]. More recently it was documented that moderate hyperglycemia per se is associated with increased risk of pregnancy complications [5]. Moreover, a mounting body of evidence point towards increased risk for cardiometabolic disorders of both mother and a child in the future [6]. However, although available data supports the screening of cardiometabolic risk factors during pregnancy and postpartum [7,8], further improvements of screening strategies are required [9]. Apart from in utero predisposition, glucose metabolism disorders in childhood and adolescence, particularly type 1 diabetes mellitus, possesses a long-lasting impact on CVD risk [10,11]. In recent years, the increasing prevalence of type 2 diabetes mellitus in pediatric population was observed, as well as its strong association with childhood obesity, sedentary lifestyle and the western pattern diet [12]. These data suggests that timely recognition and optimal management of glucose metabolism disorders and accompanying risk factors could reduce both short-term and long-term consequences of gestational and childhood-onset diabetes. Taking into account the delicacy of this issue, additional longitudinal studies with comprehensive evaluation of biomarkers associated with glucose metabolism disorders in order to reveal early signs of subclinical atherosclerosis, are highly welcomed.



**Citation:** Vekic, J.; Silva-Nunes, J.; Rizzo, M. Glucose Metabolism Disorders: Challenges and Opportunities for Diagnosis and Treatment. *Metabolites* **2022**, *12*, 712. <https://doi.org/10.3390/metabo12080712>

Received: 22 July 2022

Accepted: 26 July 2022

Published: 29 July 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Despite well-known limitations of conventional biochemical parameters for the diagnosis and treatment monitoring, clinical validation of recently proposed candidates, such as advanced glycation end-products (AGEs), fructosamine and glycated albumin, is still pending [13]. Furthermore, the integration of innovative methods in medical laboratories, such as genomic, transcriptomic, epigenomic, proteomic and metabolomic techniques, enabled a more in-depth evaluation of disease-specific molecular pathways [14]. In that sense, metabolomics studies are of particular importance for identification of novel biomarkers related to glucose metabolism disorders [13]. These emerging biomarkers could also represent potential therapeutic targets in disease management, paving the way toward more personalized strategies. Nevertheless, the implementation of metabolomics biomarkers in clinical practice is faced with several limitations, the most important being restricted availability to the clinicians, unmet need for validation and harmonization of the assays and uncertain cost-effectiveness, which require further evaluation.

One of the most prominent mechanisms involved in complex etiology of microvascular and macrovascular complications of diabetes is dyslipidemia. It is now firmly established that worsening of metabolic control triggers disorders of lipid metabolism at multiple levels [15]. Diabetic dyslipidemia is characterized by qualitative changes of plasma lipoproteins, the most prominent being increase in small, dense low-density lipoprotein (LDL) particles [16,17]. In contrast with LDL, which size is inversely related to the atherogenic potential [18], there is still no reliable answer to the question on the relationship between physico-chemical and atheroprotective properties of HDL particles in the conditions associated with high CVD risk [19]. Analysis of HDL proteome and metabolome constitutes a promising field which could provide valuable information on the relationship between the structure and function of this lipoprotein in high-risk patients [20].

In order to comprehensively present all aspects of disturbed glucose homeostasis, it is important to consider potential effects of anti-diabetic therapeutics on hyperglycemia biomarkers and associated risk factors. Data from large epidemiological studies and clinical trials have provided significant evidence that lowering fasting and post-prandial glycemia, as well as ameliorating other indices of glucose metabolism alterations, such as glycated hemoglobin (HbA<sub>1c</sub>), is an effective approach to reduce cardiometabolic risk [21]. In light of these findings, reduction of glycemic excursions is increasingly important aspect of diabetes management. However, different metrics were used to assess glycemic variability across the studies [21] and more data is needed to define the most useful indices in clinical practice. In addition, it is equally important to assess the efficacy of glycemic fluctuations control among different anti-diabetic medications and combined therapy. To date, a variety of pharmaceutical and nutraceutical approaches are available for management of diabetes and its co-morbidities. Notably, innovative anti-diabetic agents have a broad spectrum of cardioprotective mechanisms, which goes far beyond their hypoglycemic effects [22,23]. It is therefore critically important to further address which biomarkers, alone or as a multimarker panel, are the most suitable for monitoring these pleiotropic effects of novel anti-diabetic medications.

By overcoming the COVID-19 outbreak, diabetes mellitus remains the largest epidemics of the world. In the following period, it should not be neglected that diabetes is a major contributor to COVID-19 severity and mortality, as well as that the maintenance of optimal glycemic control is the key to reduce the risk from infection [24,25]. A growing trend of post-COVID patients urges the need to increase awareness about the risk of new-onset hyperglycemia or diabetes, in attempting to prevent its adverse consequences [26]. As stated above, a number of potential biomarkers of glucose metabolism disorders have been identified, but they have not yet been sufficiently explored in the post-COVID era.

This Special Issue of *Metabolites* is aimed to critically review available evidence from basic science and clinical studies on the above listed challenges that need to be met, in order to contribute to a better understanding of glucose metabolism alterations and their effective management and prevention.

**Author Contributions:** All authors have contributed equally to the presented editorial. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Acknowledgments:** J.V. appreciates the support from the Ministry of Education, Science and Technological Development, Republic of Serbia (grant no. 451-03-68/2022-14/200161).

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Vekic, J.; Zeljkovic, A.; Stefanovic, A.; Jelic-Ivanovic, Z.; Spasojevic-Kalimanovska, V. Obesity and dyslipidemia. *Metabolism* **2019**, *92*, 71–81. [[CrossRef](#)] [[PubMed](#)]
2. Grandl, G.; Wolfrum, C. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. *Semin. Immunopathol.* **2018**, *40*, 215–224. [[CrossRef](#)] [[PubMed](#)]
3. Popovic, D.S.; Rizzo, M.; Stokic, E.; Papanas, N. New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications? *Diabetes Ther.* **2021**, *12*, 1605–1611. [[CrossRef](#)] [[PubMed](#)]
4. Patti, A.M.; Giglio, R.V.; Pafili, K.; Rizzo, M.; Papanas, N. Pharmacotherapy for gestational diabetes. *Expert Opin. Pharmacother.* **2018**, *19*, 1407–1414. [[CrossRef](#)]
5. Kwapong, Y.A.; Boakye, E.; Wang, G.; Hong, X.; Lewey, J.; Mamas, M.A.; Wu, P.; Blaha, M.J.; Nasir, K.; Hays, A.G.; et al. Maternal Glycemic Spectrum and Adverse Pregnancy and Perinatal Outcomes in a Multiracial US Cohort. *J. Cardiovasc. Dev. Dis.* **2022**, *9*, 179. [[CrossRef](#)]
6. Patti, A.M.; Pafili, K.; Papanas, N.; Rizzo, M. Metabolic disorders during pregnancy and postpartum cardiometabolic risk. *Endocr. Connect.* **2018**, *7*, E1–E4. [[CrossRef](#)]
7. Zeljkovic, A.; Vekic, J.; Spasic, S.; Jelic-Ivanovic, Z.; Spasojevic-Kalimanovska, V.; Gojkovic, T.; Ardalic, D.; Mandic-Markovic, V.; Cerovic, N.; Mikovic, Z. Changes in LDL and HDL Subclasses in Normal Pregnancy and Associations with Birth Weight, Birth Length and Head Circumference. *Matern. Child Health J.* **2013**, *17*, 556–565. [[CrossRef](#)]
8. Cabunac, P.; Orlic, N.K.; Ardalic, D.; Banjac, G.; Ivanišević, J.; Janać, J.; Vekić, J.; Zeljković, A.; Mihajlović, M.; Rajović, N.; et al. Unraveling the role of oxidative stress and lipid status parameters in the onset of preeclampsia. *Hypertens. Pregnancy* **2021**, *40*, 162–170. [[CrossRef](#)]
9. Brown, S.D.; Hedderson, M.M.; Zhu, Y.; Tsai, A.-L.; Feng, J.; Quesenberry, C.P.; Ferrara, A. Uptake of guideline-recommended postpartum diabetes screening among diverse women with gestational diabetes: Associations with patient factors in an integrated health system in USA. *BMJ Open Diabetes Res. Care* **2022**, *10*, e002726. [[CrossRef](#)]
10. Bojanin, D.; Vekic, J.; Milenkovic, T.; Vukovic, R.; Zeljkovic, A.; Stefanovic, A.; Janac, J.; Ivanisevic, J.; Mitrovic, K.; Miljkovic, M.; et al. Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control. *Atherosclerosis* **2019**, *280*, 14–20. [[CrossRef](#)]
11. Kacarevic, D.; Bogavac-Stanojevic, N.; Spasojevic-Kalimanovska, V.; Bojanin, D.; Milenkovic, T.; Stefanovic, A.; Mihajlovic, M.; Vujcic, S.; Vukovic, R.; Zeljkovic, A.; et al. Factors associated with oxidative stress status in pediatric patients with type 1 diabetes mellitus. *J. Pediatr. Endocrinol. Metab.* **2020**, *33*, 591–598. [[CrossRef](#)]
12. Shah, A.S.; Nadeau, K.J.; Dabelea, D.; Redondo, M.J. Spectrum of Phenotypes and Causes of Type 2 Diabetes in Children. *Annu. Rev. Med.* **2022**, *73*, 501–515. [[CrossRef](#)]
13. Ortiz-Martínez, M.; González-González, M.; Martagón, A.J.; Hlavinka, V.; Willson, R.C.; Rito-Palomares, M. Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus. *Curr. Diabetes Rep.* **2022**, *22*, 95–115. [[CrossRef](#)]
14. Giglio, R.V.; Stoian, A.P.; Patti, A.M.; Rizvi, A.A.; Sukhorukov, V.; Ciaccio, M.; Orekhov, A.; Rizzo, M. Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome. *Curr. Pharm. Des.* **2021**, *27*, 3729–3740. [[CrossRef](#)]
15. Vergès, B. Pathophysiology of diabetic dyslipidaemia: Where are we? *Diabetologia* **2015**, *58*, 886–899. [[CrossRef](#)]
16. Vekic, J.; Zeljkovic, A.; Cicero, A.F.G.; Janez, A.; Stoian, A.P.; Sonmez, A.; Rizzo, M. Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL. *Medicina* **2022**, *58*, 299. [[CrossRef](#)]
17. Rizzo, M.; Berneis, K. The Clinical Relevance of Low-Density-Lipoproteins Size Modulation by Statins. *Cardiovasc. Drugs Ther.* **2006**, *20*, 205–217. [[CrossRef](#)]
18. Rizzo, M.; Spinass, G.A.; Cesur, M.; Ozbalkan, Z.; Rini, G.B.; Berneis, K. Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis. *Atherosclerosis* **2009**, *207*, 502–506. [[CrossRef](#)]
19. Miljkovic, M.; Stefanovic, A.; Vekic, J.; Zeljkovic, A.; Gojkovic, T.; Simic-Ogrizovic, S.; Bogavac-Stanojevic, N.; Cerne, D.; Ilic, J.; Stefanovic, I.; et al. Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease. *Clin. Biochem.* **2018**, *60*, 52–58. [[CrossRef](#)]
20. Vekic, J.; Zeljkovic, A.; Al Rasadi, K.; Cesur, M.; Silva-Nunes, J.; Stoian, A.P.; Rizzo, M. A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies. *Metabolites* **2022**, *12*, 108. [[CrossRef](#)]
21. Zhou, Z.; Sun, B.; Huang, S.; Zhu, C.; Bian, M. Glycemic variability: Adverse clinical outcomes and how to improve it? *Cardiovasc. Diabetol.* **2020**, *19*, 102. [[CrossRef](#)]

22. Rizzo, M.; Nikolic, D.; Patti, A.M.; Mannina, C.; Montalto, G.; McAdams, B.S.; Rizvi, A.A.; Cosentino, F. GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. *Biochim. Biophys. Acta Mol. Basis Dis.* **2018**, *1864*, 2814–2821. [[CrossRef](#)]
23. Rizvi, A.A.; Rizzo, M. The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction. *Diabetes Metab. Syndr. Obes.* **2022**, *15*, 1023–1030. [[CrossRef](#)]
24. Bigdelou, B.; Sepand, M.R.; Najafikhoshnoo, S.; Negrete, J.A.T.; Sharaf, M.; Ho, J.Q.; Sullivan, I.; Chauhan, P.; Etter, M.; Shekarian, T.; et al. COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes. *Front. Immunol.* **2022**, *13*, 890517. [[CrossRef](#)]
25. Stoian, A.P.; Banerjee, Y.; Rizvi, A.A.; Rizzo, M. Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management. *Metab. Syndr. Relat. Disord.* **2020**, *18*, 173–175. [[CrossRef](#)]
26. Pal, R.; Joshi, A.; Bhadada, S.K.; Banerjee, M.; Vaikkakara, S.; Mukhopadhyay, S. Endocrine Follow-up During Post-Acute COVID-19: Practical Recommendations Based on Available Clinical Evidence. *Endocr. Prac.* **2022**, *28*, 425–432. [[CrossRef](#)]